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 Cataract, the leading cause of blindness world wide, is
associated with many risk factors. Diabetes has been consid-
ered to be one of the major risk factors of cataract [1,2]. Many
experimental studies in vitro and in vivo support the view that
diabetes is a cause of cataract. Under normal conditions cellu-
lar glucose is phosphorylated by hexokinase for further utili-
zation through glycolysis or the HMPS pathway. During hy-
perglycemia cellular levels of glucose greatly increase in tis-
sues where glucose entry is independent of insulin. In these
tissues, which include lens, retina, kidney, and peripheral
nerves, this excess glucose is metabolized via an accessory
pathway known as the polyol pathway [3]. Aldose reductase
(AR: EC 1.1.1.21) is the rate-limiting enzyme of the polyol
pathway. AR catalyzes glucose to sorbitol and sorbitol dehy-
drogenase, the second enzyme of the pathway, further con-
verts sorbitol to fructose [3,4]. An AR-catalyzed formation of
sorbitol was also observed in a number of tissues and the polyol
pathway was recognized as an essential component of inter-
mediary metabolism [4-6]. Although some recent studies im-
plicate a role for AR in the detoxification of aldehydes, the
major bioactive products of lipid peroxidation [7,8], the physi-
ological relevance of this pathway and its role in overall car-
bohydrate metabolism remains unclear. Under normoglycemic
conditions, approximately 3% of the glucose metabolized is
routed via the polyol pathway [9]. However, under hypergly-
cemic conditions, this pathway accounts for more than 30%
of the glucose utilized [10]. The observations of van Heyningen
[11] that production of galactitol and sorbitol (polyols of ga-
lactose and glucose) in large quantities in rat lens during sugar-
induced cataractogenesis stimulated intense interest in the
pathological role of polyol pathway in the development of
cataract. Reduction of excess glucose to the osmolyte sorbitol
leads to osmotic swelling, changes in membrane permeabil-
ity, and subsequent cataract formation. Therefore, prevention
of polyol accumulation by inhibiting AR to prevent cataract
and other diabetes-associated ocular pathology has received
considerable attention.
The use of traditional medicines, mainly derived from
plant sources, has been a major part in the management of
many chronic ailments including diabetes, particularly in coun-
tries like India [12-14]. Moreover, there is a renewed interest
in recent times to identify as many plant sources as possible
for their therapeutic value [14,15]. A large number of plants/
spices are now well recognized to possess hypoglycemic po-
tential [12-14,16]. Most of the studies have focused only at
containing blood glucose levels, mainly as an alternative to
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Purpose: Aldose reductase (AR) has been a drug target because of its involvement in the development of secondary
complications of diabetes including cataract. Although numerous synthetic AR inhibitors (ARI) have been tested and
shown to inhibit the enzyme, clinically synthetic ARIs have not been very successful. Therefore, evaluating natural sources
for ARI potential may lead to the development of safer and more effective agents against diabetic complications. In the
present study we have assessed the inhibition of AR by constituents of Emblica officinalis both in vitro and in lens organ
culture.
Methods: E. officinalis is widely used against many chronic ailments including diabetes. Aqeous extract of E. officinalis
and its major constituent tannoids were tested for inhibition against both rat lens and purified recombinant human AR.
ARI potential of isolated tannoids of E. officinalis were also investigated against osmotic stress in rat lens organ culture.
Results: E. officinalis extract inhibited rat lens and recombinant human AR with IC50 values 0.72 and 0.88 mg/ml respec-
tively. Since E. officinalis is a rich source of ascorbic acid, we investigated whether ascorbic acid was responsible for AR
inhibition by E. officinalis extract. However, ascorbic acid did not inhibit AR even at 5 mM concentration. Further, we
demonstrate that the hydrolysable tannoids of E. officinalis were responsible for AR inhibition, as enriched tannoids of E.
officinalis exhibited remarkable inhibition against both rat lens and human AR with IC50 of 6 and 10 µg/ml respectively.
The inhibition of AR by E. officinalis tannoids is 100 times higher than its aqueous extract and comparable to or better
than quercetin. Furthermore, the isolated tannoids not only prevented the AR activation in rat lens organ culture but also
sugar-induced osmotic changes.
Conclusions: These results indicate that tannoids of E. officinalis are potent inhibitors of AR and suggest that exploring
the therapeutic value of natural ingredients that people can incorporate into everyday life may be an effective approach in
the management of diabetic complications.
Correspondence to: G. Bhanuprakash Reddy, National Institute of
Nutrition, Hyderabad - 500 007, India; FAX: 91-40-27019074; email:
geereddy@yahoo.com
148
exogenous insulin. However, many of these hypoglycemic
agents have not been investigated for their beneficial effects
on secondary complications of diabetes like cataract, retin-
opathy, nephropathy, and neuropathy. As AR inhibitors (ARIs)
have considerable clinical value in ameliorating the second-
ary complications of diabetes, it would be of great importance
to investigate ARI potential and to test the anticataractogenic
effect of these natural sources. Since most of the plant prod-
ucts including natural spices are largely free from adverse ef-
fects and are being used as a source of diet and traditional
medicine [15], testing the ARI potential of these sources may
lead to a better management of secondary complications of
diabetes.
Emblica officinalis Gaertn., commonly known as amla,
is extensively used in many preparations of Ayurveda and also
against many chronic ailments including diabetes [17-19]. In
the present study we have assessed the ARI potential of amla
and report that tannoid principles of amla are potent inhibitors
of rat lens AR and also human recombinant AR. We also show
that tannoid principles of amla prevent the sugar-induced
polyol stress in cultured rat lenses and together these results
imply that amla ingredients may be explored as an
anticataractogenic agent for diabetic cataract.
METHODS
Materials:  DL-glyceraldehyde, glucose, lithium sulfate, 2-
mercaptoethanol, NADPH, quercitin, dimethylsulfoxide, TC-
199 medium (M-3769), sorbitol, sorbitol dehydrogenase,
NAD, and glutathione reductase were purchased from Sigma
Chemical Company (St. Louis, MO). Tannoid principles from
amla were isolated according to Ghosal et al. [20] and ob-
tained in the form of a standardized mixture of emblicanin A,
emblicanin B, punigluconin, and pedunculagin from Indian
Herbs Research & Supply Company (Saharanpur, India). The
U. S. patent number for the product is 6,124,268 and further
details can be obtained from the U. S. Patent Office.
Rat lens aldose reductase:  Crude aldose reductase was
prepared from rat lens. Eyeballs were removed from 9 week
old WNIN male rats obtained from National Center for Labo-
ratory Animal Services, National Institute of Nutrition,
Hyderabad. Animal care and protocols were in accordance with
and approved by Institutional Animal Ethics Committee.
Lenses were dissected by posterior approach and homogenized
in 10 volumes of 100 mM potassium phosphate buffer pH 6.2.
The homogenate was centrifuged at 15,000x g for 30 min at 4
°C and the resulting supernatant was used as the source of
AR.
Purification of recombinant human aldose reductase:
Recombinant human aldose reductase was purified from bac-
terial cultures. Enzyme from expression cultures was extracted
and purified essentially as described previously [21] with the
exception that affinity chromatography over AffiGel Blue (Bio-
Rad) was used as a final purification step.
Extraction of E. officinalis fruit:  Fresh fruits of E.
officinalis were obtained from the local market. The pericarp
was collected and freeze-dried. Dried material was powdered
and a water extract was prepared by stirring at room tempera-
ture for 3 h. Insoluble material was removed by centrifuga-
tion followed by filtration. The water extract was freeze-dried
and stored under desiccation at 4 °C.
Aldose reductase assay:  AR activity was assayed accord-
ing to the method described by Hayman and Kinoshita [22].
The assay mixture in 1 ml contained 50 µM potassium phos-
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Figure 1. Inhibition of aldose reductase by aqueous extract of E.
officinalis.  Representative plot of inhibition of rat lens AR (A) and
human recombinant AR (B) by aqueous extracts of E. officinalis. AR
activity in the absence of E. officinalis extract was considered as
100%.
TABLE 1. INHIBITION OF ALDOSE REDUCTASE (AR) BY ASCORBIC ACID
Ascorbic    Rat lens       Human
acid (mM)      AR      recombinant AR
---------   --------   --------------
  0          100           100
  0.01        98.6          98.3
  0.1         97.8          98.8
  1.0         95.2          96.6
  5.0         96.2          95.8
Values are expressed as percent residual activity and are averages of
three independent experiments.
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phate buffer pH 6.2, 0.4 m M lithium sulfate, 5 µM 2-mercapto
ethanol, 10 µM DL-glyceraldehyde, 0.1 µM NADPH, and
enzyme preparation (rat lens or recombinant enzyme). Ap-
propriate blanks were employed for corrections. The assay
mixture was incubated at 37 °C and initiated by the addition
of NADPH at 37 °C. The change in the absorbance at 340 nm
due to NADPH oxidation was followed in a Cary Bio 100
spectrophotometer.
Inhibition studies:  For inhibition studies concentrated
stocks of aqueous extract of amla or mixture of isolated tannoid
principles were prepared in water and quercetin was prepared
in DMSO. Various concentrations of inhibitors were added to
the assay mixture and incubated for 5-10 min before initiating
the reaction by NADPH as described above. The percent of
inhibition with test compounds was calculated considering the
AR activity in the absence of inhibitor was 100%. The con-
centration of each test sample giving 50% inhibition (IC50)
was then estimated.




 of rat lens AR and re-
combinant AR were determined with varying concentrations
of glyceraldehydes in the absence and presence of tannoid




 were estimated by Lineweaver-
Burk double reciprocal plots.
Lens organ culture studies:  Eyes were enucleated from 2
month old WNIN rats immediately after sacrifice by cervical
dislocation. Lenses were dissected from the eyes by posterior
approach. Each isolated lens was incubated in 2 ml modified
TC-199 medium with antibiotics (filtered through 0.2 µm
Millipore disc filters) according to the method of Zigler and
Hess [23]. They were incubated at 37 °C under 95% air and
5% CO2 with and without 55 mM glucose for a period of 18 h
(for sorbitol estimation) or for 4 days (for lens morphology).
Medium was changed for every 48 h. Lenses incubated in the
medium containing a normal glucose concentration (5.5 mM)
and 30 mM fructose (for maintaining similar osmolarity) were
considered as control lenses. When added to medium, a stock
mixture of tannoids of amla was prepared in water and fil-
tered through 0.2 µm filters (Millipore).
Estimation of sorbitol in the lens:  For extraction of sor-
bitol the lens was homogenized in 9 volumes of 0.8 M per-
chloric acid. The homogenate was centrifuged at 5,000x g at 4
°C for 10 min and the pH of the supernatant was adjusted to
3.5 with 0.5 M potassium carbonate. The sorbitol content of
the supernatant was measured by an enzymatic method as de-
scribed previously [24].
Estimation of vitamin C in amla extract:  The amount of
vitamin C present in aqueous extracts of amla used for AR
inhibition was estimated by HPLC according to a previously
described method [25]. One ml of 1% aqueous extract of amla
was precipitated with 0.35 M perchloric acid and centrifuged
at 10,000x g for 15 min. The supernatant was filtered through
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Figure 2. Major hydrolysable tannoids of E. officinalis.  Structures
of the major tannoids of E. officinalis, emblicanin A (A), emblicanin
B (B), punigluconin (C), and pedunculagin (D). While emblicanin A
has one R1 and one R2 side groups, emblicanin B has two R2 side
groups.
Figure 3. Inhibition of aldose reductase by tannoids of E. officinalis.
Representative graph of inhibition of rat lens AR (A) and human
recombinant AR (B) by isolated tannoids of E. officinalis (solid
circles) and quercetin (open circles).
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0.45 µm filters (Millipore) and loaded onto a C18 reversed phase
column as described in [25].
RESULTS & DISCUSSION
E. officinalis is extensively found throughout India and some
other Asian countries. The fruits are widely consumed raw,
cooked, or pickled. The fruits of the plant form a major con-
stituent of many potent Ayurveda preparations [17]. These
preparations are widely used for their preventive, curative, and
health restorative properties. It possesses very good
hypocholesterolemic [18], anticarcinogenic [26], antidiabetic
[19], and antioxidant properties [19,27-29]. Therefore, we have
investigated amla for its inhibitory potential against rat lens
and human recombinant AR.
 As shown in Figure 1A, aqueous extracts of E. officinalis
inhibited rat lens AR, with an IC50 value of 0.72 mg/ml. How-
ever, rat lens is known to have the highest AR activity com-
pared to other species [30]. Moreover, the other constituents
in the crude preparation of rat lens AR could complicate the
results of AR inhibition by amla. Thus the relevance of inhibi-
tion of rat lens AR by E.officinalis may have limited applica-
tion to human diabetic cataract. Therefore, we have also as-
sessed the inhibitory potential of E. officinalis against puri-
fied human recombinant AR expressed in E. coli. Interestingly
aqueous extracts of E. officinalis inhibited human recombi-
nant AR to the same extent as that of rat lens AR with an IC50
value of 0.88 mg/ml (Figure 1B). The results using a pure
preparation of human AR not only substantiate the inhibition
of rat lens AR by amla, but also indicate that any artifacts that
could have possibly occurred with crude preparations of rat
lens AR are not significant. Since amla is a rich source of
vitamin C (ascorbic acid), it is believed that the major con-
stituent responsible for most of the biological actions of amla
is vitamin C. Further, it was reported that vitamin C can in-
hibit human erythrocyte AR [31]. Nevertheless, the reported
vitamin C content in amla varies from negligible to 0.7% [20].
Hence, we have estimated the amount of vitamin C present in
the water extract of amla that was used for AR inhibition stud-
ies by HPLC. One gram of amla extract was found to have 1.2
mg of vitamin C (0.12%). We then assessed the inhibitory ef-
fect of ascorbic acid against both rat lens and human recombi-
nant AR. As shown in Table 1, vitamin C did not inhibit AR at
concentrations as high as 5 mM, thus suggesting that AR inhi-
bition by E. officinalis is due to some other constituents other
than vitamin C.
It is interesting to note other studies indicating that the
biological actions, particularly antioxidant activities, of amla
can not be attributed to ascorbic acid alone [27-29]. The po-
tent vitamin C-like activity, antioxidative effect of amla fruit
against reactive oxygen species, was observed with low mo-
lecular weight hydrolysable tannins [20]. Four such com-
pounds, emblicanin A, emblicanin B, punigluconin, and
pedunculagin have been isolated from amla pericarp and their
structures have been established [20]. The first two compounds
are naturally occurring galloellagi-tannins, which were nei-
ther identified earlier in nature nor were prepared syntheti-
cally. The other two compounds (punigluconin and
pedunculagin) were identified by correspondence of their prop-
erties to those of previously reported from other plant species
[20]. The chemical nature of the major tannoids of amla,




hexahydroxydiphenoyl gluconic acid, and 2,3,4,6-bis(S)-
hexahydroxydiphenoyl-D-glucose, respectively [20] (Figure
2). Recently, Bhattacharya et al. [28,29] demonstrated the an-
tioxidant property for the tannoid rich fraction of E. officinalis
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Figure 4. Nature of inhibition of aldose reductase by E. officinalis
tannoids.  Representative double-reciprocal plots of rat lens AR (up-
per graph) and human recombinant AR (lower graph) in the presence
(open circles) and absence (closed circles) of tannoids of E. officinalis.
TABLE 2. IC50 VALUES OF E. OFFICINALIS TANNOIDS AND QUERCETIN
FOR INHIBITION OF AR
            Rat lens       Human
Inhibitor      AR      recombinant AR
---------   --------   --------------
Emblica
Tannoids      6.1            9.8
Quercetin     9.2           13.5
Values are in µg/ml and are an average of three independent experi-
ments.
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in a stress induced oxidative damage model in rat brain. There-
fore, we have obtained the enriched fraction of E. officinalis
juice with the above tannoids as a standardized extract and
investigated the inhibitory effects against AR in vitro and in
lens organ culture. The relative proportions of different
tannoids in the standardized extract are, emblicanin A and B-
35-55%, punigluconin-4-15%, pedunculagin-10-20%, rutin-
3%, and gallic acid-1%.
As shown in Figure 3, a mixture of tannoid principles
isolated from amla exhibited remarkable inhibition against both
rat lens AR and human recombinant AR. The inhibitory po-
tential of isolated tannoids of amla was about 100 times greater
compared to the aqueous extract of amla and suggests their
potential application in the prevention of sugar cataract. The
IC50 values obtained with rat lens and recombinant AR for
amla tannoids were 6 and 10 µg/ml respectively (Table 2). On
comparison with IC50 values of quercetin, a well known natu-
ral flavonoid with aldose reductase inhibitory potential [32],
tannoids of amla appear to be more potent (Table 2). We have









 with glyceraldehyde as substrate indicate that tannoids
inhibit AR in an uncompetitive manner (Figure 4 and Table
3). To rule out the possibility that tannoids may also inhibit
other enzymes in a non-specific manner, we have tested
whether tannoids inhibit glutathione reductase and rat lens
glucose-6-phosphate dehydrogenase. Neither aqueous extract
nor the tannoid mixture of amla inhibited these enzymes (data
not shown).
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TABLE 3. KINETIC PARAMETERS OF RAT LENS AND HUMAN RECOMBI-
NANT AR IN THE ABSENCE AND PRESENCE OF TANNOIDS OF E.
OFFICINALIS
                Rat lens AR       Human recombinant AR
            -------------------   --------------------
 Kinetic      (-)        (+)        (-)        (+)
parameter   Tannoids   Tannoids   Tannoids   Tannoids
---------   --------   --------   --------   ---------
 Km (mM)      0.279     0.161*      0.085     0.037*
             ±0.032    ±0.022      ±0.017    ±0.013
  Vmax       24.2      10.6*        3.88      1.72*
             ±1.57     ±1.42       ±0.219    ±0.231
V
max
 is reported as µmoles NADPH oxidized/h/100 mg for rat lens
AR or µmoles NADPH oxidized/min/mg for human recombinant AR.
Asterisks (*) indicate a statistically significant difference from the
values in the absence of tannoids (Student’s t-test, p<0.001). Values
are mean±standard deviation (n=5).
TABLE 4. EFFECT OF E. OFFICINALIS TANNOIDS ON ALDOSE REDUCTASE
ACTIVITY AND SORBITOL LEVELS IN LENS CULTURE
 Group     AR activity   Sorbitol
--------   -----------   --------
Control       26.4        19.4
              ±2.45       ±1.74
Glucose       36.2*       83.1*
55 mM         ±3.51       ±9.13
Glucose       29.8#       67.2*#




AR activity and sorbitol levels were measured in rat lens incubated
in the presence of normal (5.5 mM) and high (55 mM) glucose for 18
h. AR activity is expressed as µmoles NADPH oxidized/h/100 mg
protein and sorbitol is expressed as nmoles/100 mg lens. The aster-
isks (*) indicate a statistically significant difference from the control
group and the sharps (#) indicate a statistically significant difference
from the glucose 55 mM group (ANOVA, p<0.05). Values are
mean±standard deviation of three independent experiments.
Figure 5. Effect of E. officinalis tannoids on lens transparency under osmotic conditions.  Morphology of lens in organ culture: Rat lenses were
cultured in modified TC-199 as described in Methods in the presence of 5.5 mM glucose and 30 mM fructose, control lens (A), 55 mM glucose
(B), and 55 mM glucose along with 50 µg/ml tannoid mixture of amla (C).
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Accumulation of high concentrations of polyols in the
lens leads to excessive hydration, gain of sodium, and loss of
potassium ions due to an increase in intracellular ionic strength
[3]. Also there is a loss of membrane permeability and leak-
age of free amino acids, glutathione, myoinositol, and other
small molecular weight substances. The resulting hyper os-
motic stress associated oxidative insult is postulated to be the
primary cause for the development of diabetic complications
such as cataract, retinopathy, neuropathy, and nephropathy
[33]. To understand the significance of in vitro inhibition of
AR by amla, the effect of isolated tannoids against osmotic
stress were investigated in lens organ culture. Rat lenses incu-
bated with 55 mM glucose for 18 h developed vacuoles and
AR activity significantly increased compared to lenses incu-
bated with a normal glucose (5.5 mM) concentration along
with fructose (30 mM, Table 4). Incubation of lenses with 55
mM glucose also resulted in increased production of sorbitol
compared to control lenses (Table 4). While the lens incu-
bated with 55 mM glucose for 4 days became cloudy and lost
transparency, the morphology of the lens incubated with 55
mM glucose along with 50 µg/ml of tannoid mixture of amla
appears similar to control lenses even after 4 days (Figure 5).
More importantly, activation of AR and increased sorbitol lev-
els due to hyperglycemic stress was prevented when lenses
were incubated with 55 mM glucose in the presence of 50 µg/
ml amla tannoids in the medium (Table 4). While the mixture
of E. officinalis tannoids was not effective at concentrations
<10 µg/ml, a concentration >100 µg/ml in the medium im-
parts some color to lenses (data not shown). The results indi-
cate that the in vitro inhibition of AR by E. officinalis could
be correlated with in vivo conditions as it prevented changes
associated with AR activation in lens organ culture.
Due to its proposed involvement in the development of
diabetic complications, AR has been a drug target in the clini-
cal management of secondary complications of diabetes in-
cluding cataract [34]. Structurally distinct compounds such as
flavonoids, benzopyrans, spirohydantoins, alkaloids, nonste-
roidal anti-inflammatory agents, and quinones have all been
shown to inhibit the enzyme with various degrees of efficacy
and specificity [6,35]. Sorbinil, statil, tolrestat, alrestatin,
epalrestat, and ALO1576 are some of the well-studied inhibi-
tors that have also been clinically tested. However, to date,
none of the currently available synthetic ARIs have proved
clinically effective and some have in fact had deleterious side
effects. Moreover there is an increased interest in recent times
to identify many natural (plant/spice) sources for their thera-
peutic properties, mainly because most of the plant and plant
products (including natural spices) are largely free from ad-
verse effects and are being used as a source of diet and tradi-
tional medicine. Recently a few other plant products have been
reported to inhibit crude rat lens AR [36-38]. Therefore, we
are interested in screening plant/spice sources for their
anticataractogenic potential and in this context the results of
inhibition of AR by E. officinalis suggest that screening of
dietary components for AR inhibition could lead to the devel-
opment of possibly safer and more effective agents than other
known ARIs against diabetic cataract. Studies are underway
to investigate the anticataractogenic effect of E. officinalis and
its constituent tannoids against diabetic cataract in animal
models.
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